Curium

Based in Paris, France, and founded in 2012, Curium, formerly IBA Molecular Imaging (radiopharmaceutical division of IBA) operates as a medical company that designs and manufactures radiopharmaceutical products, radioactive compounds, and nuclear tracers for detecting cancer. As of 2022, the company employs around 2300 employees, has more than 6,000 customers, and is led by its CEO, Renaud Dehareng. In March 2016, CapVest Associates agreed to acquire IBA Molecular Imaging for EUR 200 million. In 2017, IBA Molecular and Mallinckrodt Nuclear Medicine LLC were united to create a radiopharmaceutical company, Curium.

Curium offers nuclear medicines that employ small amounts of radioactive isotopes to detect and treat diseases that affect organs ranging from the thyroid, lungs, liver, and bones to the brain, heart, and glands. As of 2022, the company's nuclear medicine product portfolio includes more than 50 products such as generators, cold kits, hot products, and auxiliary products, and its production operations are divided into three suboperations: European, Canada, and the United States, each of which sells medicines and products under different brands such as Cisnaf®, Gallium 67Ga, Nanocis®, Pulmocis®, and Technescan MAG3TM. As of 2022, the company operates one moly processing unit, four production plants, and more than 45 radiopharmacy.